Biogen Inc. (BIIB) Stock Forecast
BIIB analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.17 / 5 from 36 analysts
- Price target
- $243.98 average of analyst targets
- Upside to target
- +4.9% from the latest close
- Next earnings
- October 28, 2026 EPS estimate $2.10
- 52-week range
- $146.22 – $235.35
BIIB analyst ratings
36 analystsNumber of analysts at each rating.
BIIB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BIIB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.00 | $1.44 | $2.67 | $4.81 | −58.5% | 27 |
| Current fiscal year (2026) | $12.53 | $11.76 | $16.39 | $15.28 | −18.0% | 34 |
| Next fiscal year (2027) | $16.52 | $13.64 | $18.67 | $12.53 | +31.9% | 32 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BIIB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.63B | $2.50B | $2.75B | +3.8% | 27 |
| Current fiscal year (2026) | $10.44B | $10.10B | $10.65B | +5.5% | 33 |
| Next fiscal year (2027) | $10.64B | $9.91B | $11.13B | +1.9% | 31 |
BIIB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BIIB revenue: reported and forecast
BIIB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.96 | $2.04 | $2.03 | $2.02 | $2.00 | −32.5% | 2 up · 2 down |
| Current fiscal year (2026) | $12.58 | $12.41 | $12.54 | $12.53 | $12.53 | −0.4% | 2 up · 3 down |
| Next fiscal year (2027) | $16.55 | $16.54 | $16.54 | $16.52 | $16.52 | −0.1% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BIIB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BIIB beat in 12 of 12.
What analysts expect from BIIB
36 analysts cover Biogen; their consensus rating is buy (4.17 on a 1–5 scale, where 5 is a strong buy). The average price target is $243.98, 4.9% above the latest close of $232.65. Analysts expect earnings of $12.53 per share for 2026, −18.0% from a year earlier. For 2027 the average estimate is $16.52 per share on revenue of $10.6 billion. Biogen beat the EPS estimate in 12 of the last 12 quarters.
Related: BIIB income statement, BIIB key metrics, BIIB chart. See the BIIB stock overview for the latest quote and news.
BIIB forecast FAQ
What is Biogen's price target?
The average analyst price target for Biogen is $243.98, 4.9% above the latest close of $232.65.
Is Biogen a buy, hold or sell?
Of 36 analysts covering Biogen, 20 rate it a strong buy, 4 a buy, 11 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Biogen's EPS forecast?
Analysts forecast $12.53 per share for 2026 (range $11.76 to $16.39); for 2027 the estimate is $16.52.
What is Biogen's revenue forecast?
The average revenue estimate for 2026 is $10.4 billion, growth of 5.5%; for 2027 it is $10.6 billion.
When does Biogen report earnings?
Biogen is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 before the market opens; the EPS estimate is $2.10.
Does Biogen usually beat earnings estimates?
Biogen reported EPS at or above the analyst estimate in 12 of the last 12 quarters.